{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:36:25Z","timestamp":1780104985714,"version":"3.54.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1053\/bega.2003.0361","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T18:13:53Z","timestamp":1046801633000},"page":"131-137","source":"Crossref","is-referenced-by-count":59,"title":["Crohn's disease: step up or top down therapy"],"prefix":"10.1053","volume":"17","author":[{"given":"Stephen B.","family":"Hanauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/bega.2003.0361_RF1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00054725-199512000-00007","article-title":"Standards for approval of new drugs for IBD","volume":"1","author":"Fredd","year":"1995","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0361_RF2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF3","article-title":"Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis","volume":"2","author":"Sutherland","year":"2000","journal-title":"Cochrane Database Systems Review"},{"key":"10.1053\/bega.2003.0361_RF4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0361_RF7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0361_RF10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease (in process citation)","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/bega.2003.0361_RF12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF14","series-title":"Points to Consider on Clinical Investigation of Medicinal Products for the Management of Crohn's Disease","year":"2001"},{"key":"10.1053\/bega.2003.0361_RF15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM199603283341307","article-title":"Review articles: drug therapy: inflammatory bowel disease","volume":"334","author":"Hanauer","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"Systematic review: the effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1053\/bega.2003.0361_RF20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease","volume":"339","author":"Thomsen","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0016-5085(82)80189-3","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result","volume":"83","author":"Ursing","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1572-0241.1999.935_q.x","article-title":"A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease","volume":"94","author":"Colombel","year":"1999","journal-title":"American Journal of Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00054725-199503000-00006","article-title":"A critical review of cyclosporine therapy in inflammatory bowel disease","volume":"1","author":"Sandborn","year":"1995","journal-title":"Infammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0361_RF24","first-page":"876","article-title":"Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease","volume":"92","author":"Sandborn","year":"1997","journal-title":"American Journal of Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF26","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease (Cochrane Review)","volume":"1","author":"Simms","year":"2001","journal-title":"Cochrane Database Systems Review"},{"key":"10.1053\/bega.2003.0361_RF27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0016-5085(82)80332-6","article-title":"Metronidazole therapy for perineal Crohn's disease: a follow-up study","volume":"83","author":"Brandt","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF28","first-page":"CD000301","article-title":"Corticosteroids for maintaining remission of Crohn's disease","author":"Steinhart","year":"2001","journal-title":"Cochrane Database Systems Review"},{"key":"10.1053\/bega.2003.0361_RF29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0361_RF30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0016-5085(00)70208-3","article-title":"Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI","volume":"118","author":"Lochs","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF33","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/0016-5085(95)90121-3","article-title":"Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection (see comments)","volume":"108","author":"Rutgeerts","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF35","doi-asserted-by":"crossref","first-page":"A688 (abstract)","DOI":"10.1016\/S0016-5085(98)84115-2","article-title":"Postoperative prophylaxis with 6MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial","volume":"114","author":"Korelitz","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF36","article-title":"Azathioprine or 6-Mercaptopurine for inducing remission of Crohn's disease","volume":"2","author":"Sandborn","year":"2000","journal-title":"Cochrane Database Systems Review"},{"key":"10.1053\/bega.2003.0361_RF37","first-page":"CD000067","article-title":"Azathioprine for maintaining remission of Crohn's disease","author":"Pearson","year":"2000","journal-title":"Cochrane Database Systems Review"},{"key":"10.1053\/bega.2003.0361_RF38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease","volume":"342","author":"Feagan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0016-5085(98)70381-6","article-title":"Inflammatory bowel disease: etiology and pathogenesis","volume":"115","author":"Fiocchi","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0361_RF42","first-page":"71","article-title":"Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease","volume":"47","author":"Nikolaus","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/bega.2003.0361_RF43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1053\/bega.2003.0361_RF44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/003655298750027290","article-title":"Azathioprine: state of the art in inflammatory bowel disease","volume":"225","author":"Sandborn","year":"1998","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis (in process citation)","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF46","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0016-5085(99)70411-7","article-title":"From immune activation to gut tissue injury: the pieces of the puzzle are coming together","volume":"117","author":"Fiocchi","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF47","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0140-6736(02)08590-2","article-title":"Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study","volume":"359","author":"Hampe","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/bega.2003.0361_RF48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort","volume":"117","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF49","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1572-0241.2000.02000.x","article-title":"Medical therapy to reduce postoperative Crohn's disease recurrence","volume":"95","author":"Achkar","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1053\/bega.2003.0361_RF50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00054725-200108000-00014","article-title":"The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease","volume":"7","author":"Cho","year":"2001","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691803903611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691803903611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T19:49:16Z","timestamp":1584474556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691803903611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S1521691803903611"],"URL":"https:\/\/doi.org\/10.1053\/bega.2003.0361","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}